Here you will find our latest news and updates.

September 2019 updates to website


The website has now been updated following September’s LSCMMG

The following drugs have been added/updated:

Ciclosporin 0.1% / 1 mg/mL eye drops (Verkazia®) — Severe vernal keratoconjunctivitis in children from 4 years of age and adolescents

Azelastine hydrochloride/Fluticasone propionate 137mcg/50mcg (120d) (Dymista ®) — Relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

Fluocinolone Acetonide —  Intravitreal implant for treating recurrent noninfectious uvetitis (NICE TA590)

Risankizumab — For treating moderate to severe plaque psoriasis (NICE TA596)

Dapagliflozin — Dapagliflozin with insulin for treating type 1 diabetes (NICE TA 597)

The following guidelines have been added/updated:

Vitamin D (Version 3.0) — Position Statement — Update

Camouflaging Products (Version 1.1) — Position Statement — Update

Trans Female Gender Dysphoria (Version 1.1) — Prescribing Information Sheet — Update

Combined Adult and Child ADHD (Version 1.1) — Guideline — Update

Psoriasis — LSCMMG Biologic & High Cost Drugs Commissioning Pathway (Version 1.6) — Guideline — Update

Home Monitoring of Blood Glucose Levels  — Guideline — Update